Doctors Say Earlier Mesothelioma Diagnosis Might Be Possible with MicroRNAs, According to Surviving Mesothelioma

Share Article

Scientists in Italy say tiny portions of RNA molecules might hold the key to identifying malignant mesothelioma in asbestos-exposed people.

Diagnosing Mesothelioma Earlier

miRNA Biomarkers for Mesothelioma

The qualitative meta-analysis...confirmed the early diagnostic value of two miRNA signatures for malignant mesothelioma...

Researchers at the Universita Politecnica delle Marche in Ancona combed medical journal articles to find the most commonly-identified miRNAs in people with peritoneal or pleural mesothelioma. Their findings are the subject of a new article on the Surviving Mesothelioma website. Click here to read it now.

Diagnostic biomarkers are signposts in the blood, lung fluid or tissue of mesothelioma patients that can help point doctors to the presence of the asbestos cancer.

“The qualitative meta-analysis and functional investigation confirmed the early diagnostic value of two miRNA signatures for malignant mesothelioma,” writes lead study author Luigina Micolucci with the Universita Politecnica delle Marche in Ancona.

Reporting on their findings in the journal Oncotarget, the team called the pool of identified potential miRNA mesothelioma biomarkers “mesomiRs” and said, with more study, they may even prove to be important therapeutic targets.

“Early diagnosis of malignant mesothelioma remains a huge clinical challenge,” says Surviving Mesothelioma Managing Editor Alex Strauss. “This study is the latest in a growing body of research suggesting that miRNAs may play a key role in changing that and, potentially, improving mesothelioma survival.”

For more on mesothelioma biomarkers and the potential of miRNAs, see Earlier Mesothelioma Diagnosis with MicroRNAs now available on the Surviving Mesothelioma website.

Minolucci, L, et al, “Diagnostic valu eof micoRNAs in asbestos exposure and laignant mesothelioma: systematic review and qualitative meta-analysis”, June 1, 2016, Oncotarget, Epub ahead of print, http://www.ncbi.nlm.nih.gov/pubmed/27259231

For nearly ten years, Surviving Mesothelioma has brought readers the most important and ground-breaking news on the causes, diagnosis and treatment of mesothelioma. All Surviving Mesothelioma news is gathered and reported directly from the peer-reviewed medical literature. Written for patients and their loved ones, Surviving Mesothelioma news helps families make more informed decisions.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Michael Ellis
Cancer Monthy
+1 (919) 570-8595
Email >
Follow us on
Visit website